Gilead Sciences, Inc. (NASDAQ:GILD) Given Consensus Rating of “Hold” by Analysts

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) have earned a consensus recommendation of “Hold” from the eighteen analysts that are covering the stock, Marketbeat.com reports. Twelve analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $83.47.

A number of research analysts have recently weighed in on GILD shares. Robert W. Baird reissued a “neutral” rating and set a $80.00 target price on shares of Gilead Sciences in a research report on Thursday, June 20th. Morgan Stanley lowered their target price on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a report on Friday, April 26th. StockNews.com raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 27th. Royal Bank of Canada reiterated a “sector perform” rating and set a $74.00 price objective on shares of Gilead Sciences in a research note on Friday, June 14th. Finally, UBS Group cut their target price on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th.

Gilead Sciences Stock Down 0.3 %

Gilead Sciences stock opened at $68.61 on Friday. Gilead Sciences has a twelve month low of $62.07 and a twelve month high of $87.86. The firm has a 50 day moving average price of $65.98 and a 200-day moving average price of $72.58. The company has a market capitalization of $85.48 billion, a P/E ratio of 190.58, a P/E/G ratio of 2.93 and a beta of 0.20. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The firm had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. During the same period in the prior year, the firm earned $1.37 EPS. The company’s revenue was up 5.3% compared to the same quarter last year. As a group, equities analysts predict that Gilead Sciences will post 3.75 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, June 27th. Stockholders of record on Friday, June 14th were issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.49%. The ex-dividend date of this dividend was Friday, June 14th. Gilead Sciences’s payout ratio is 855.56%.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the transaction, the insider now owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

Several institutional investors and hedge funds have recently made changes to their positions in GILD. Tompkins Financial Corp grew its holdings in shares of Gilead Sciences by 223.1% during the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 241 shares during the last quarter. Fortitude Family Office LLC purchased a new stake in Gilead Sciences during the 4th quarter valued at $29,000. Private Wealth Management Group LLC purchased a new stake in Gilead Sciences during the 4th quarter valued at $29,000. Palisade Asset Management LLC purchased a new stake in Gilead Sciences during the 1st quarter valued at $29,000. Finally, Sachetta LLC purchased a new stake in Gilead Sciences during the 4th quarter valued at $30,000. Institutional investors own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.